Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
Lara S van der SchootJuul M P A van den ReekLynda GrineLisa SchotsWietske KievitJo L W LambertElke M G J de JongPublished in: Trials (2021)
ClinicalTrials.gov NCT04340076 . Registered on April 9 2020.